Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin swaps on Liquid resume but peg-outs frozen; reserves 603 BTC short, L-BTC 85.8% backed

Market News
20 Oct 2026
Tokenpost
View Source
Bearish
Bitcoin swaps on Liquid resume but peg-outs frozen; reserves 603 BTC short, L-BTC 85.8% backed

Bitcoin swaps on the Liquid network have restarted, yet direct peg-outs remain frozen, preventing full redemption of L-BTC tokens. The reserves backing L-BTC are currently about 603 BTC short, meaning only approximately 85.8% of outstanding L-BTC is fully backed. This situation limits holders from fully redeeming their tokens, raising concerns about liquidity and trust in the platform. The resumption of swaps indicates partial recovery but full peg-out functionality is still pending resolution.

Bitcoin swaps on the Liquid network have restarted while direct peg-outs remain frozen, with L-BTC reserves about 603 BTC short. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 03:41 WIB: out of 50 major cryptocurrencies, 45 rose and 4 fell today. Notable movers include BAL at Rp16.297 (+11.14%), EOS at Rp12.649 (+8.13%), and VET at Rp127 (+5.47%) with a typical hold time of 148 days on Pluang.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
1 hour ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
2 hours ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
2 hours ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App